Chinese Drugmaker Lands Warning Letter for Data Mishandling

International Pharmaceutical Regulatory Monitor
A A
The FDA has faulted an API maker for a host of failings at its production facility in China, including tampering with official records.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor